Antibodies for SARS-CoV-2 Immunoassay Development

The major method currently being used to determine active infections is PCR testing, which detects viral RNA. However, due to several major drawbacks of PCR assays, alternative tests, such as antigen testing, are being explored. Antigen tests are immunoassays that detect the presence of a viral proteins, which implies a current viral infection. R&D Systems offers antibodies directed against SARS-CoV-2 antigens, such as the S1 and S2 subunits, as well as the Nucleocapsid Protein, for development of SARS-CoV-2 antigen tests.

We are the Experts in Producing Antibodies for Assay Development

R&D Systems has over 30 years of experience in developing antibodies. These antibodies are used by our development scientists to produce our wide range of immunoassay products, including our Quantikine^® ELISA kits, the industry’s gold standard ELISAs.

Our Antibodies are Scalable to Gram Quantities

Because we manufacture the antibodies we sell, we can produce large quantities of your antibody of interest. Bulk ordering of your antibody means you will have a long-term supply of a reliably performing product, thus minimizing the likelihood that you will experience inconsistent performance of your immunoassay.

We are Committed to Providing Quality Products

Our quality standards are unmatched in the industry. Unlike our competition, we can develop and manufacture most of our antibodies in-house. This allows us to conduct quality tests that are not available to most life science reagent companies and thus offer consistently performing, high-quality antibodies to the biomedical field. Additionally, all our products are manufactured under compliance with ISO 9001:2008 and/or ISO 13485:2003/CMDR guidelines. To learn more about our commitment to quality, visit our Quality page and/or Review Our Certifications.